Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 6/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.54 |
| ▸ | ACACA | Q13085 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593342 | 0.89 | TNKS (0.52) | TNKSTNKS2PARP2ACACAGRM2 | |
| SCHEMBL6079947 | 0.89 | ACACA (0.55) | TNKSTNKS2PARP2ACACAGRM2 | |
| SCHEMBL6079925 | 0.83 | SLC6A4 (0.44) | TNKSTNKS2PARP2SLC6A4SLC6A3 | |
| SCHEMBL6080006 | 0.82 | NQO2 (0.47) | TNKSTNKS2PARP2PDE10AMRGPRX4 | |
| SCHEMBL6081341 | 0.81 | PDE10A (0.47) | TNKSTNKS2PARP2PDE10AMRGPRX4 | |
| SCHEMBL1811362 | 0.81 | ALOX15 (0.50) | TNKSTNKS2PARP2PDE10APARP1 | |
| SCHEMBL1811192 | 0.79 | PDE10A (0.61) | TNKSTNKS2PARP2ACACAGRM2 | |
| SCHEMBL561666 | 0.78 | PDE10A (0.47) | TNKSTNKS2PARP2PDE10APARP1 | |
| SCHEMBL6080246 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A3MRGPRX4KDM4E | |
| SCHEMBL28879004 | 0.77 | ACACA (0.55) | TNKSTNKS2PARP2ACACAGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | TNKS 1332/4885TNKS2 1619/4885PARP2 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.